

Susanna Naggie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1303188/publications.pdf>

Version: 2024-02-01

64
papers

2,652
citations

201674

27
h-index

189892

50
g-index

66
all docs

66
docs citations

66
times ranked

3910
citing authors

#	ARTICLE	IF	CITATIONS
1	Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015, 373, 705-713.	27.0	432
2	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	12.8	194
3	Risk Factors for and Estimated Incidence of Community-associated <i>Clostridium difficile</i> Infection, North Carolina, USA. <i>Emerging Infectious Diseases</i> , 2010, 16, 197-204.	4.3	186
4	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2010, 24, F23-F29.	2.2	184
5	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction. <i>Gastroenterology</i> , 2010, 139, 1181-1189.e2.	1.3	171
6	Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 6-12.	5.8	133
7	A Case-control Study of Community-associated <i>Clostridium difficile</i> Infection: No Role for Proton Pump Inhibitors. <i>American Journal of Medicine</i> , 2011, 124, 276.e1-276.e7.	1.5	84
8	Molds: Hyalohyphomycosis, Phaeohyphomycosis, and Zygomycosis. <i>Clinics in Chest Medicine</i> , 2009, 30, 337-353.	2.1	67
9	Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. <i>Hepatology</i> , 2011, 53, 389-395.	7.3	67
10	Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response. <i>Hepatology</i> , 2012, 56, 444-454.	7.3	61
11	Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 1-21.	4.5	58
12	Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. <i>Annual Review of Medicine</i> , 2017, 68, 345-358.	12.2	57
13	COVID-19—Lessons Learned and Questions Remaining. <i>Clinical Infectious Diseases</i> , 2021, 72, 2225-2240.	5.8	54
14	Genotype 3 Infection: The Last Stand of Hepatitis C Virus. <i>Drugs</i> , 2017, 77, 131-144.	10.9	52
15	Assessment of <i>Clostridium difficile</i> Associated Disease Surveillance Definitions, North Carolina, 2005. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 197-202.	1.8	51
16	Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 407-413.	5.8	49
17	The Prevalence and Burden of Non-AIDS Comorbidities Among Women Living With or at Risk for Human Immunodeficiency Virus Infection in the United States. <i>Clinical Infectious Diseases</i> , 2021, 72, 1301-1311.	5.8	46
18	Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. <i>Clinical Infectious Diseases</i> , 2017, 64, 1035-1042.	5.8	42

#	ARTICLE	IF	CITATIONS
19	Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx264.	0.9	42
20	Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2166-2172.	4.4	40
21	A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360) Tj ETQq1 1 0.784314 rgBT /Overlock 107, 307-317.	8.1	39
22	Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2063-2069.	3.0	38
23	New Therapeutics for Hepatitis B: The Road to Cure. <i>Annual Review of Medicine</i> , 2021, 72, 93-105.	12.2	38
24	Successes and Challenges on the Road to Cure Hepatitis C. <i>PLoS Pathogens</i> , 2015, 11, e1004854.	4.7	36
25	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 256-268.	4.4	34
26	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383.	4.0	31
27	Protease inhibitor-based antiretroviral therapy in treatment-naïve HIV-1-infected patients: the evidence behind the options. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1094-1099.	3.0	30
28	An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1083-1091.	2.3	27
29	A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. <i>Hepatology</i> , 2020, 71, 1894-1909.	7.3	24
30	Health Care Utilization in HIV-Infected Patients: Assessing the Burden of Hepatitis C Virus Coinfection. <i>AIDS Patient Care and STDs</i> , 2012, 26, 541-545.	2.5	22
31	Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. <i>Journal of Cardiac Failure</i> , 2018, 24, 496-503.	1.7	22
32	Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. <i>Clinical Infectious Diseases</i> , 2019, 69, 514-522.	5.8	20
33	Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014. <i>Current HIV/AIDS Reports</i> , 2013, 10, 408-419.	3.1	17
34	Management of hepatitis C virus infection: the basics. <i>Topics in Antiviral Medicine</i> , 2012, 20, 154-61.	0.1	15
35	Retreatment Options Following HCV Direct-Acting Antiviral Failure. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 389-402.	1.9	14
36	Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 528-531.	5.8	13

#	ARTICLE	IF	CITATIONS
37	Benefits of Direct-Acting Antivirals for Hepatitis C. <i>Annals of Internal Medicine</i> , 2017, 167, 812.	3.9	13
38	Hepatitis C Virus Elimination in the Human Immunodeficiency Virusâ€“Coinfected Population. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 407-423.	5.1	12
39	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. <i>Clinical Infectious Diseases</i> , 2017, 65, 1773-1775.	5.8	11
40	Metabolites predict cardiovascular disease events in persons living with HIV: a pilot caseâ€“control study. <i>Metabolomics</i> , 2018, 14, 1.	3.0	11
41	Management of Hepatitis C in 2019. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 355.	7.4	9
42	Incident Non-AIDS Comorbidity Burden Among Women With or at Risk for Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e2059-e2069.	5.8	9
43	Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw173.	0.9	8
44	Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw258.	0.9	8
45	The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx267.	0.9	7
46	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2018, 72, 73-85.	1.8	7
47	Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3394-3401.	2.3	6
48	Cardiovascular Disease Risk Management in Persons With HIV: Does Clinician Specialty Matter?. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa361.	0.9	6
49	Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection. <i>Journal of Infectious Diseases</i> , 2020, 222, 2012-2020.	4.0	5
50	A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). <i>Contemporary Clinical Trials Communications</i> , 2021, 24, 100851.	1.1	4
51	Treating HCV Infection: It Doesn't Get Much Better Than This. <i>Topics in Antiviral Medicine</i> , 2019, 26, 104-108.	0.1	4
52	Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfecting patients with incomplete hepatitis B virus viral suppression. <i>Hepatology</i> , 2016, 64, 999-1000.	7.3	3
53	Comments on cochrane review on directâ€“acting antivirals for hepatitis C. <i>Hepatology</i> , 2017, 66, 1016-1019.	7.3	3
54	Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform. <i>Contemporary Clinical Trials</i> , 2021, 109, 106525.	1.8	3

#	ARTICLE	IF	CITATIONS
55	Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy138.	0.9	2
56	Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?. <i>Hepatology Communications</i> , 2019, 3, 453-455.	4.3	2
57	Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 630-636.	2.0	2
58	COVID-19 Trials: Who Participates and Who Benefits?. <i>Southern Medical Journal</i> , 2022, 115, 256-261.	0.7	2
59	Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800006.	1.6	1
60	Hepatitis C Behind and Beyond Bars. <i>North Carolina Medical Journal</i> , 2019, 80, 352-355.	0.2	1
61	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. <i>Journal of Infectious Diseases</i> , 2020, 222, S741-S744.	4.0	1
62	Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv066.	0.9	0
63	2549. Variance Between Clinicians and Guidelines in Management of HIV/HCV Coinfection. <i>Open Forum Infectious Diseases</i> , 2019, 6, S886-S886.	0.9	0
64	301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections. <i>Open Forum Infectious Diseases</i> , 2019, 6, S162-S162.	0.9	0